The Governance Gap in Pharma AI Adoption
Every pharmaceutical company is now evaluating AI tools for its medical affairs workflows. The technology pitch is compelling: faster document retrieval, more consistent responses to HCP questions, fewer hours spent on manual search before a scientific exchange. The decision to adopt, however, should not be made primarily on the technology. It should be made on the governance structure that will surround the technology once it is deployed.
Medical affairs operates in a regulated environment where the accuracy of clinical information shared with healthcare professionals is not just a quality standard. It is a legal and regulatory obligation under FDA promotional regulations and ICH guidelines for good clinical practice. A system that makes it faster to share clinical information also makes it faster to share incorrect clinical information if the underlying governance architecture is wrong. Speed amplifies both directions.
The framework we describe below is not a checklist to rush through in order to start a pilot. It is a set of structural questions that a medical affairs leadership team, in collaboration with legal, regulatory affairs, and IT, should answer before any AI tool is deployed beyond an exploratory proof-of-concept stage. The questions are harder than they look, and the answers will differ across organizations depending on size, regulatory jurisdiction, and the specific workflows being automated.
First Principle: AI in Medical Affairs Should Not Make Autonomous Clinical Judgments
This is the foundational principle, and it is worth stating plainly before going into process details. The value of an AI tool in medical affairs is in retrieval, synthesis, and preparation assistance. It is not in replacing the human judgment that decides whether a specific piece of clinical information is appropriate to share in a specific context with a specific healthcare professional.
An MSL asking "what does the label say about dose reduction in patients with moderate renal impairment?" is asking a retrieval question. The correct AI output is the relevant label section, cited precisely, so the MSL can read it and use it in context. That is appropriate AI assistance. An AI system that outputs "you should tell this physician to reduce the dose by 50%" is making a clinical communication decision. That decision belongs to the MSL and their medical affairs function, informed by the document, not made by the system.
This distinction sounds obvious, but it is easy for product design and user experience to blur the line. An AI tool that presents answers in a confident, declarative tone can create an implicit suggestion of authority that a careful reading of the underlying document would not support. The design of responsible AI tools for medical affairs should actively preserve this boundary, not through friction for its own sake, but through consistent framing that keeps the human in the position of reader and judge, and the AI in the position of retrieval assistant.
Validation: What It Means for an AI Retrieval Tool
The word "validation" means different things in different parts of the pharmaceutical organization. For a clinical operations team, validation refers to 21 CFR Part 11 computer system validation for GCP-regulated clinical trial data systems. For a medical affairs AI tool, the regulatory requirements are different, but the underlying logic of validation applies: before you rely on a system for a regulated purpose, you need evidence that the system performs as intended across a representative range of conditions.
For a source-grounded retrieval tool used in medical affairs, validation should address at minimum: retrieval accuracy (does the system find the correct document and section in response to representative queries?), citation accuracy (when the system returns a citation with page and section, does that citation actually point to the source of the answer?), and failure mode characterization (when the system cannot find a reliable answer, does it say so, or does it construct a plausible but unsupported response?).
Validation does not need to wait for full formal computerized systems validation in the 21 CFR Part 11 sense unless the tool is being integrated into a GCP-regulated workflow. For most MSL preparation and scientific exchange support uses, a documented user acceptance testing protocol with a representative set of queries, evaluated by qualified medical affairs reviewers, provides a reasonable baseline for deployment confidence. The key is that someone has systematically tested the system on the type of queries it will actually be used for, and has documented the results.
Human-in-the-Loop: Defining Where the Handoff Must Happen
Human-in-the-loop is a phrase that gets used loosely. For a governance framework, it needs to be defined precisely: in which specific workflow steps must a qualified human review and approve the AI-assisted output before it influences a regulated action or external communication?
For MSL meeting preparation, the workflow is internal: the MSL uses the AI tool to gather and organize source-grounded information in preparation for a scientific exchange. The human-in-the-loop is the MSL themselves, who reads the cited sources, assesses accuracy and context, and decides what to discuss with the HCP. No formal approval workflow is required at this stage because no external communication has yet occurred.
For medical information request responses, the workflow has higher stakes. A drafted response based on AI-assisted retrieval is going to a healthcare professional who will make patient care decisions based on it. Here, human-in-the-loop means a medically qualified reviewer, typically a physician or pharmacist in the medical information department, formally reviews and approves the response before it is transmitted. The AI assists the drafting and sourcing; the human makes the decision to send.
For any workflow where AI-assisted outputs could directly appear in an external communication to an HCP without human review, the answer is simple: that workflow should not be deployed. Not because the AI is necessarily wrong, but because the accountability structure for externally shared medical information requires a qualified human to own the decision.
Change Management: Training the Team to Use AI Tools Appropriately
Deploying an AI tool in medical affairs without investing in how the team is trained to use it is one of the more common ways responsible deployment breaks down in practice. The training need is not technical. Most MSLs can learn the mechanics of a query interface in an hour. The training need is behavioral: understanding what the tool is designed to do and, equally important, what it is not designed to do.
Training should cover several things. First, how to evaluate an AI-generated response: the expectation should be that the MSL reads the cited source, not just the AI-generated answer. A response that looks plausible but cites a source without checking is not source-grounded use. It is copy-paste use with a citation badge. Second, how to handle situations where the tool returns a low-confidence result or cannot find relevant information: the correct action should be explicit, whether that is consulting the medical information team, searching a different document set, or escalating to a medical affairs colleague. Third, what types of queries are out of scope: questions about unapproved indications, questions that would require medical judgment about a specific patient case, and questions about competitive products in contexts not covered by approved scientific exchange guidance.
This training should be documented and completed before deployment, and refreshed when the tool is updated significantly or when the document corpus changes substantially (for example, after a major label update).
Audit and Ongoing Oversight
A responsible adoption framework does not end at deployment. It includes an ongoing oversight mechanism that detects when the system is being used outside intended parameters, when user behavior suggests the human-in-the-loop is being bypassed, or when document changes have introduced accuracy gaps in retrieved content.
The minimum viable audit structure for a medical affairs AI tool includes: query logging that records what users searched for and what the system returned, reviewed periodically by a medical affairs compliance function; periodic accuracy spot-checks where a sample of queries and responses is reviewed by a qualified medically trained reviewer against the source documents; and a clear process for users to flag apparent inaccuracies or unexpected system behavior for investigation.
The audit function also serves a documentation purpose that matters in a regulated environment: if a compliance question arises about what information was available to an MSL at a specific point in time, query logs provide a traceable record. This is not about surveillance of employees. It is about having the documentation infrastructure to demonstrate that the team's AI tool use was consistent with the governance framework in place.
The Question of Vendor Accountability
Responsible adoption also requires that the AI vendor share accountability for the governance framework, not just the pharma company. The vendor's product design choices directly determine whether source-grounding is genuine or cosmetic, whether the system presents uncertainty appropriately, and whether audit logging is available. These are vendor decisions that the adopting organization cannot control after deployment.
This is why vendor assessment, covered separately in our data privacy vendor evaluation article, is part of the governance framework, not separate from it. Before deploying an AI tool in medical affairs, you should have reviewed the vendor's model design for hallucination mitigation, confirmed the source-grounding architecture is document-level and citation-precise, and verified that the vendor can answer basic questions about how the system handles low-confidence retrievals.
We will say this plainly for Argon: we built the source-grounding architecture first, before the interface, because we knew the accountability structure our customers would be operating under. Every answer returns the source document, section, and page because that is the requirement for a medical affairs team to use the answer responsibly. The tool should make it easier to do the right thing, not require the user to remember to do extra steps to verify the AI's output.
Starting with the Right Scope
A responsible adoption framework does not require deploying across all medical affairs workflows simultaneously. The practical approach is to start with the workflow where the governance requirements are clearest, the potential for harm from retrieval errors is lowest, and the value proposition is most direct. MSL internal preparation, where the MSL reads and evaluates the output before any external communication occurs, satisfies all three criteria. It is a good starting scope precisely because the human review layer is inherent to the workflow.
Medical information request drafting support is the logical next scope expansion, with the formal human-in-the-loop approval step built into the process before any response is transmitted. Field scientific exchange real-time query support for MSLs in active HCP meetings is a third scope, appropriate only after the team has demonstrated disciplined source-checking behavior in the lower-stakes preparation workflow.
Each expansion of scope should be accompanied by the corresponding validation, training, and audit framework updates. The governance should grow with the deployment, not be retrofitted after something goes wrong.